Logo ABD

HEALTH

INVESTMENT YEAR

2013

TEAM

16

Therapies targeting resistant cancers

Advanced Biodesign is a French biotechnology company developing a new form of targeted therapy to treat resistant cancers.

  • Advanced Biodesign will begin its safety phase (First-in-Human) for the drug candidate, ABD-3001 (clinical formulation of DIMATE) in the fall of 2022. The safety and tolerance of our lead compound as well as the biological markers of efficacy will be assessed in patients with acute myeloid leukemia (AML). A phase II/III is planned in the LAM in 2025 and 2026.
  • ABD will accelerate its preclinical development on second-generation ALDH (ALDHi) inhibitors for which patents have recently been filed and will offer it protection until 2040. One of these inhibitors will be evaluated during a clinical trial in a solid tumor (probably lung cancer) in 2025-2026.

Dedicated team


Pierre Le Sourd

Member of the Supervisory Board of Xerys Invest

Pierre Tambourin

Member of the Xerys Invest Strategic Committee

Aïda Thiam

Account manager

Recent Posts


Advanced Biodesign

Advanced BioDesign (ABD) is developing two large-scale projects in human health: Sefaldin and Sepdiak -2

SEFALDIN (cancer treatment) ABD, having acquired a unique expertise in the field of cancer, is developing a new cancer treatment ...
Read more...

XERYS FRANCE

73 boulevard haussmann

75008 Paris - France

+33 (0)1 82 52 12 25

FOLLOW-US:
error: Content is protected !!